Thirty. That's the final count of municipalities that filed tax appeals against not-for-profit hospitals in the state by April 1, according to the New Jersey Hospital Association.
St. David's expansion includes buying troubled Forest Park hospital | Austin (Texas) American-Statesman
St. David's HealthCare is buying a new hospital that never opened in far north Austin, Texas, expanding two of its largest hospitals and opening an emergency department in Leander, where it expects to build that community's first hospital.
Texas Health outbids Methodist in $117M auction of Forest Park hospital in Fort Worth | Dallas Business Journal
Intense bidding drove up the price of Forest Park Medical Center in Fort Worth, but eventually Arlington-based Texas Health Resources triumphed over Methodist Health System. THR will pay $116.5 million for the facility, which was previously physician-owned. That business model failed, forcing the hospital system into bankruptcy. Expect the same companies to bid on other Forest Park locations.
Doctors' group attacks Highmark incentive plan | Pittsburgh Tribune-Review
The president of the Pennsylvania Medical Society said Thursday that a reimbursement program from insurer Highmark worth as much as $5.5 million doesn't make up for cutting payments to doctors who treat patients with federal Affordable Care Act health insurance plans.
CDC urges hospitals to follow mold protocol | Pittsburgh Post-Gazette
The federal Centers for Disease Control and Prevention has yet to conclude the investigation it began last September of why four transplant patients at UPMC contracted mold infections and later died. But its 17-member investigative team made clear in a “Notes from the Field” report it put online Thursday that it is still focused on the negative pressure room that three of the four patients stayed in at UPMC Presbyterian—and it is recommending that other hospitals not do what UPMC did.
Harvard Medical School is relaxing a conflict-of-interest policy that prohibits some researchers from conducting clinical trials on new treatments when they have a financial stake in the company developing them.